An interventional study of renal artery fractional flow reserve measurement and dopamine in Renal Artery Stenosis Atherosclerotic and Secondary Hypertension Renal Arterial, sponsored by Peking University First Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by Peking University First Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.
Among the 410 studies in Hypertension with a site in China, this one is the 171st largest by planned enrollment of the 308 interventional ones that give a count, is one of 48 that started in 2025, is one of 146 with no phase, reaches primary completion later than 121 of the 147 other live ones, and was the 344th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
410 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 48 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 308 interventional studies, 1,000 across the 102 observational. Of the 161 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 410 have an industry lead sponsor. The 10 most frequent:
Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.
Peking University First Hospital has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
47 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 47 to your calendar (.ics) → With an account.
Among the 410 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective: To determine whether percutaneous renal artery stenting guided by fractional flow reserve (FFR), in addition to standard medical therapy, provides superior therapeutic efficacy compared to medical therapy alone in patients with atherosclerotic renal artery stenosis and hypertension.
Study Design: A double-blind, multicenter, prospective, randomized, placebo-controlled (sham procedure) trial.
Primary Endpoint: The percentage reduction in daytime mean systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 3 months after the procedure.
Study Population: A total of 200 patients who are potential candidates for renal artery intervention will be enrolled. Participants must meet all of the following inclusion criteria to be eligible for the study.
Participant Screening and Enrollment: Once a patient is preliminarily assessed in the outpatient clinic and meets the clinical inclusion/exclusion criteria, written informed consent will be obtained, and the patient will enter a 1-week screening period. During this period, patients will perform home blood pressure monitoring using a calibrated Bluetooth-enabled device provided by the study team, which automatically uploads data. In addition, antihypertensive medications will be standardized to optimize blood pressure management.
If home BP measurements during the screening period continue to meet inclusion criteria, baseline ABPM will be conducted.
Following standardized renal angiography, patients whose renal anatomy meets the angiographic inclusion/exclusion criteria will undergo functional assessment of the stenotic lesion using a pressure wire and measurement of renal fractional flow reserve (FFR) under dopamine-induced maximal hyperemia, in accordance with the Standard Operating Procedure (SOP).
Patients who qualify will then be randomized based on FFR results using an Interactive Response Technology (IRT) system. All eligible patients will be assigned a unique subject identification number during screening, and randomization will occur on the day of angiography, ensuring allocation concealment and unbiased group assignment.
Study Intervention: Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).
If FFR \< 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms:
All participants, regardless of group assignment, will receive guideline-directed optimized medical therapy throughout the study period.
Study Duration and Follow-up: Participants will be followed for a total of 12 months with study visits scheduled at the following time points:
To minimize the impact of antihypertensive medication adjustments on statistical outcomes, it is strongly recommended that no changes be made to antihypertensive regimens during the first 3 months after enrollment unless clinically necessary, such as in cases of:
To ensure consistency and quality, standardized recommendations for antihypertensive drug selection and adjustment will be provided in accordance with current hypertension management guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
If FFR ≥ 0.80, no renal artery stenting will be performed.
Diagnostic Test: renal artery fractional flow reserve measurement · Drug: dopamine
If FFR \< 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms: Stenting Group: Renal artery tenting
Diagnostic Test: renal artery fractional flow reserve measurement · Drug: dopamine · Device: renal artery stent
If FFR \< 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms: Control Group: Sham procedure
Diagnostic Test: renal artery fractional flow reserve measurement · Drug: dopamine · Other: sham stenting
Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).
Administer dopamine at 50 µg/kg via the renal artery to induce hyperemic.
Stent will be treated for the stenotic renal artery for patients randomized to stenting group
For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines.
The percentage reduction in daytime mean systolic blood pressure measured by ambulatory blood pressure monitoring from baseline to 3 months post-procedure.
Time frame: from baseline to three months after procedure
Percentage change in the composite index of antihypertensive medication use
Time frame: from baseline to 3 months post-procedure
Percentage reduction in 24-hour/daytime/nighttime mean systolic blood pressure measured by ambulatory blood pressure monitoring
Time frame: from baseline to 3 months post-procedure
Percentage reduction in systolic blood pressure measured by home blood pressure monitoring
Time frame: from baseline to 3 months post-procedure
Percentage reduction in office systolic blood pressure
Time frame: from baseline to 3 months post-procedure
Change in the number of antihypertensive medications
Time frame: from baseline to 3 months post-procedure
Number of hypertensive emergencies
Time frame: from baseline to 3 months post-procedure
Percentage reduction in daytime mean systolic blood pressure by ambulatory blood pressure monitoring
Time frame: from baseline to 6 months post-procedure
Percentage reduction in daytime mean systolic blood pressure by ambulatory blood pressure monitoring
Time frame: from baseline to 12 months post-procedure
All-cause mortality
Time frame: 1 year post-procedure
Cardiovascular death
Time frame: 1 year post-procedure
Acute myocardial infarction
Time frame: 1 year post-procedure
Non-fatal stroke
Time frame: 1 year post-procedure
Rehospitalization for congestive heart failure
Time frame: 1 year post-procedure
Progression of renal insufficiency (change in eGFR) or need for dialysis
Time frame: 1 year post-procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Aug 2028, 36 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 36 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital →